Basic Information
Eylea
Regulatory Information
EMEA/H/C/002392
November 21, 2012
September 20, 2012
36
March 5, 2025
Company Information
Germany
Kaiser-Wilhelm-Allee 1 51373 Leverkusen
BAYER AG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Eylea is indicated for adults for the treatment of: - neovascular (wet) age-related macular degeneration (AMD); - visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); - visual impairment due to diabetic macular oedema (DME); - visual impairment due to myopic choroidal neovascularisation (myopic CNV).
Overview Summary
Eylea is a medicine used to treat adults with: - the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling; - impaired vision due to macular oedema (swelling) that follows blockage of either the main vein carrying blood from the retina (known as central retinal vein occlusion, CRVO) or of smaller branch veins (known as branch retinal vein occlusion, BRVO); - impaired vision due to macular oedema caused by diabetes; - impaired vision due to myopic choroidal neovascularisation (a severe type of short-sightedness where the eyeball continues to grow, becoming longer than it should be). Eylea is also used to treat preterm infants with retinopathy of prematurity (ROP), an eye condition that can occur when a baby is born too early and blood vessels in the eye do not develop normally, causing damage to the retina. Eylea is used for specific stages of the disease: zone I (stage 1+, 2+, 3 or 3+) and zone II (stage 2+ or 3+) as well as the rapidly progressing severe form of the disease called aggressive posterior retinopathy disease. Eylea contains the active substance aflibercept.